Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Motivational Enhancement System for Adherence

This study has been completed.
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier:
NCT01009749
First received: November 6, 2009
Last updated: May 8, 2014
Last verified: May 2014

November 6, 2009
May 8, 2014
August 2009
May 2011   (final data collection date for primary outcome measure)
  • To assess the feasibility and acceptability of the Motivational Enhancement System for Adherence (MESA) among HIV-infected youth newly beginning HAART; and in an attention control condition plus standard care. [ Time Frame: 26 months ] [ Designated as safety issue: No ]
  • To compare levels of motivation to adhere and adherence and reductions in HIV-1 viral loads at follow-up among youth randomized to MESA plus standard care versus those randomized to MESH plus standard care. [ Time Frame: 26 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01009749 on ClinicalTrials.gov Archive Site
  • To compare service utilization rates among youth randomized to MESA plus standard care versus those in an attention control condition plus standard care. [ Time Frame: 26 months ] [ Designated as safety issue: No ]
  • To examine self-efficacy for adherence for youth randomized to MESA plus standard care compared to those in an attention control condition plus standard care. [ Time Frame: 26 months ] [ Designated as safety issue: No ]
  • To assess HAART medication knowledge among youth randomized to MESA plus standard care versus those in an attention control condition plus standard care. [ Time Frame: 26 months ] [ Designated as safety issue: No ]
  • To assess levels of motivation and self-efficacy for healthy eating and exercise among youth randomized to MESH plus standard care compared to those randomized to MESA plus standard care. [ Time Frame: 26 months ] [ Designated as safety issue: No ]
  • To examine the levels of nutrition and exercise knowledge among youth randomized to MESH plus standard care compared to those randomized to MESA plus standard care. [ Time Frame: 26 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Motivational Enhancement System for Adherence
Computer-Delivered Motivational Intervention to Prevent Adherence Problems Among Youth Newly Recommended for HIV Medications: Project MESA (Motivational Enhancement System for Adherence)

This is a two-phase study, consisting of the following plan:

Phase I - This is a pre-test of the feasibility and acceptability of the beta version of a computer-delivered intervention, Motivational Enhancement System for Adherence (MESA), as well as the control intervention Motivational Enhancement System for Health (MESH) at three selected AMTUs. Following analysis of the responses in Phase I and further modification of the intervention, Phase II will be initiated.

Phase II - This is a pilot, randomized, controlled trial (RCT) testing a two-session computer-delivered intervention, MESA, designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications, as well as an attention control, MESH, matched for dose and delivery format. Phase II is open to all 15 AMTUs.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
HIV
  • Behavioral: Motivational Enhancement System for Adherence (MESA)
    MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
  • Behavioral: Motivational Enhancement System for Health (MESH)
    Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
  • Experimental: MESA
    Intervention: Behavioral: Motivational Enhancement System for Adherence (MESA)
  • Active Comparator: MESH
    Intervention: Behavioral: Motivational Enhancement System for Health (MESH)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
76
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

Phase I & II, all participants

  • Engaged in care at the enrolling AMTU;
  • HIV-1 infection documented by a positive result on any of the following licensed tests at any time: any HIV-1 antibody test confirmed by Western blot, HIV-1 culture, HIV-1 DNA PCR, or plasma HIV-1 RNA PCR > 1,000 copies/ml;
  • Age 16 to 24 years, inclusive at the time of enrollment;
  • Naïve to antiretroviral therapy; NOTE: Females who have received antiretroviral therapy for the sole purpose of preventing maternal to child transmission (MTCT) will be considered antiretroviral naïve.
  • Ability to understand written and/or spoken English;
  • Willingness to provide signed informed consent/assent in either English or Spanish; and
  • Parental or legal guardian permission, if warranted.

Phase I MESA Participants/Phase II All Participants - Recommended by a health care provider to start HAART for treatment of HIV-1 infection within the 12 weeks prior to protocol screening.

Phase I MESH Participants

- Not recommended by a health care provider to start HAART for treatment of HIV-1 infection.

Exclusion Criteria:

Phase I & II, all participants

  • Known pregnancy (pregnancy testing is not required);
  • Inability to understand spoken or written English;
  • Visibly distraught and/or visibly emotionally unstable (e.g., exhibiting suicidal, homicidal, manic or violent behavior);
  • Active drug or alcohol use or dependence that, in the opinion of the site personnel, would interfere with ability to give true informed consent and to adhere to the study requirements;
  • Active psychiatric condition that in the opinion of the site personnel, would interfere with the ability to give true informed consent and to adhere to the study requirements;
  • Acute illness that, in the opinion of the treating clinician, would interfere with the participant's ability to adhere to the protocol requirements and/or interfere with the protocol objectives; and
  • Concurrent participation or participation within the previous 4 weeks, in any behavioral intervention study or program, including, but not limited to, ATN 069 and ATN 073. Permission to co-enroll into other behavioral studies or programs must be obtained from the protocol chair or designee.

Phase II, All Participants Prior participation in the Phase I MESA intervention (Phase I MESH control participants are eligible to participate).

Both
16 Years to 24 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico
 
NCT01009749
ATN 072
Yes
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • National Institute on Drug Abuse (NIDA)
  • National Institute of Mental Health (NIMH)
Study Chair: Sylvie Naar-King, PhD Adolescent Trials Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP